Friday, October 30, 2026

AI

250 articles

C3.ai AI Stock Rebounds: Is It Time to Buy Now?

C3.ai AI Stock Rebounds: Is It Time to Buy Now?

C3.ai shares have rebounded 6% after a recent decline, sparking questions about whether it's an undervalued opportunity. With a year-to-date loss of 60.69%, investors are reassessing growth prospects. The stock's price-to-sales ratio of 5x is above industry averages, raising concerns about relative valuation.

Via News Editorial•
Stock Market Rises Amid Hopes of Recovery, But AI-Driven Valuations Remain Concerning

Stock Market Rises Amid Hopes of Recovery, But AI-Driven Valuations Remain Concerning

US stock futures rose on a shortened Thanksgiving week, signaling potential recovery after a pullback amid concerns over AI-driven market rally valuations. The Dow, S&P 500, and Nasdaq all gained ground, but major indexes have lost notable ground in November as investors reassess high valuations in tech stocks.

Via News Editorial•
AI Stocks Set to Outperform Apple by 2026: Key Analysis

AI Stocks Set to Outperform Apple by 2026: Key Analysis

AI stocks Alphabet and Microsoft are poised to outperform Apple by year-end 2026, according to a detailed analysis. With faster growth and lower valuations, these stocks are expected to surpass Apple's market cap.

Via News Editorial•
AMD vs. Intel: Which Chipmaker Is Poised for Explosive Data Center Growth?

AMD vs. Intel: Which Chipmaker Is Poised for Explosive Data Center Growth?

AMD and Intel are at the forefront of data center competition as AI infrastructure continues to grow. AMD's MI300 and MI400 GPUs have seen significant success, while Intel's data center business has struggled. With $4.3 billion in revenue for AMD and $4.1 billion for Intel in the third quarter of 2025, AMD's full-stack approach could provide a strategic advantage over Intel.

Via News Editorial•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com